Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
8.35
0.18 (2.20%)
May 20, 2022 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Selling, General & Admin | 15.73 | 4.01 | 0.64 |
| Research & Development | 57.16 | 24.01 | 7.35 |
| Operating Expenses | 72.88 | 28.01 | 7.99 |
| Operating Income | -72.88 | -28.01 | -7.99 |
| Interest Expense / Income | 0 | 0 | -0 |
| Other Expense / Income | 1.08 | 7.87 | -0.25 |
| Pretax Income | -73.96 | -35.88 | -7.74 |
| Net Income | -73.96 | -35.88 | -7.74 |
| Net Income Common | -73.96 | -35.88 | -7.74 |
| Shares Outstanding (Basic) | 25 | 2 | 5 |
| Shares Outstanding (Diluted) | 25 | 2 | 5 |
| Shares Change | 1548.09% | -69.66% | - |
| EPS (Basic) | -2.96 | -23.65 | -1.55 |
| EPS (Diluted) | -2.96 | -23.65 | -1.55 |
| Free Cash Flow Per Share | -2.76 | -17.43 | -1.51 |
| EBITDA | -71.83 | -35.34 | -7.67 |
| EBIT | -73.96 | -35.88 | -7.74 |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).